| Ixinity (trenonacog alfa) / Medexus |
2021-005356-10: A pivotal study of N-Acetyl-L-Leucine on Niemann-Pick disease type C |
|
|
| Ongoing | 3 | 53 | Europe, RoW | N-acetyl-L-leucine, IB1001, Granules for oral suspension in sachet | IntraBio Ltd, IntraBio Ltd | Niemann-Pick Disease type C (NPC) Niemann-Pickovu chorobu typu C, Niemann-Pick Disease type C (NPC) Niemann-Pickovu chorobu typu C, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
NCT05163288: A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C |
|
|
| Active, not recruiting | 3 | 53 | Europe, US, RoW | N-Acetyl-L-Leucine, IB1001, Placebo | IntraBio Inc | Niemann-Pick Disease, Type C | 06/23 | 11/24 | | |
NCT06673056: A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T) |
|
|
| Not yet recruiting | 3 | 60 | Europe, US | N-Acetyl-L-Leucine, IB1001, levacetylleucine, Placebo | IntraBio Inc | Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T) | 12/27 | 06/28 | | |
NCT03759639: N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) |
|
|
| Completed | 2 | 33 | Europe, US | IB1001, N-Acetyl-L-Leucine | IntraBio Inc | Niemann-Pick Disease, Type C | 11/22 | 11/22 | | |
2018-004331-71: To demonstrate that N-Acetyl-L-Leucine is effective in improving symptoms, functioning and quality of life in patients with Niemann-Pick Type C disease (NPC). |
|
|
| Not yet recruiting | 2 | 39 | Europe, RoW | N-Acetyl-L-Leucine, IB1001, Powder for oral suspension, Granules for oral suspension | IntraBio Ltd, IntraBio Ltd, | To demonstrate that N-Acetyl-L-Leucine is effective in improvingsymptoms, functioning, and quality of life in patients withNiemann-Pick Type C disease (NPC)., Niemann-Pick Type C (NPC) is a rare inherited neurodegenerative disease that occurs when the cerebellum becomes inflamed or damaged., Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-004406-25: To demonstrate that N-Acetyl-L-Leucine is effective in improving symptoms, functioning and quality of life in patients with GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease). |
|
|
| Not yet recruiting | 2 | 39 | Europe, RoW | N-Acetyl-L-Leucine, IB1001, Powder for oral suspension, Granules for oral suspension | IntraBio Ltd, IntraBio Ltd, | To demonstrate that N-Acetyl-L-Leucine is effective in improvingsymptoms, functioning, and quality of life in patients GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)., Tay–Sachs disease (α-mutations) and Sandhoff disease (β-mutations) are neurovisceral autosomal-recessive inherited metabolic, lysosomal storage disorder (LSD)., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT03759665: N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) |
|
|
| Completed | 2 | 30 | Europe, US | IB1001, N-Acetyl-L-Leucine | IntraBio Inc | GM2 Gangliosidosis, Tay-Sachs Disease, Sandhoff Disease | 01/23 | 01/23 | | |
| Recruiting | 2 | 39 | Europe, US | IB1001, N-Acetyl-L-Leucine | IntraBio Inc | Ataxia Telangiectasia, Louis Bar Syndrome | 12/24 | 03/25 | | |
| BAT (botulism antitoxin heptavalent) / Emergent Biosolutions |
NCT02051062: BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients |
|
|
| Enrolling by invitation | 4 | 10 | NA | Blood sample collection | Emergent BioSolutions | Botulism | 07/27 | 07/27 | | |
| CNJ-016 (vaccinia immune globulin intravenous (human)) / Emergent Biosolutions |
NCT01374984: VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection |
|
|
| Enrolling by invitation | N/A | 100 | NA | VIGIV, Vaccinia Immune Globulin Intravenous (Human) | Emergent BioSolutions, Centers for Disease Control and Prevention | Complication of Smallpox Vaccination | 08/25 | 08/25 | | |
| Anthrasil (anthrax Immune Globulin) / Emergent Biosolutions |
NCT03569514: Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax |
|
|
| Not yet recruiting | N/A | 10 | NA | AIGIV, ANTHRASIL® | Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services | Anthrax | 07/26 | 07/26 | | |
NCT03569553: A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients |
|
|
| Not yet recruiting | N/A | 100 | NA | AIGIV, ANTHRASIL® | Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services | Inhalational Anthrax | 07/26 | 07/26 | | |
| NuThrax (AV7909) / Emergent Biosolutions |
| Active, not recruiting | 2 | 220 | NA | AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL) | Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., ICON plc | Anthrax | 08/25 | 08/26 | | |
| Completed | 1 | 41 | US | AV7909 | National Institute of Allergy and Infectious Diseases (NIAID) | Anthrax, Anthrax Immunisation | 11/23 | 03/24 | | |
| Abthrax (raxibacumab) / Emergent Biosolutions |
NCT02177721: Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis |
|
|
| Not yet recruiting | 4 | 100 | NA | Collection of samples | Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services, GlaxoSmithKline | Infections, Bacterial | 07/25 | 07/25 | | |
| VLA1601 / Emergent Biosolutions, Valneva |
VLA1601-102, NCT06334393: Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults |
|
|
| Recruiting | 1 | 150 | US | VLA1601, CpG 1018®, 3M-052-AF | Valneva Austria GmbH | Zika, Zika Virus Infection | 07/25 | 12/26 | | |
| nanoparticle universal influenza vaccine (UniFlu) / Emergent Biosolutions |
| Completed | 1 | 27 | RoW | UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose, Placebo | Emergent BioSolutions | Human Influenza | 10/23 | 10/23 | | |
| PXVX0317 / Bavarian Nordic |
| Completed | 3 | 3258 | US | CHIKV VLP/adjuvant, Placebo | Bavarian Nordic, Emergent BioSolutions | Chikungunya Virus | 04/23 | 04/23 | | |
NCT05349617: Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years |
|
|
| Completed | 3 | 413 | US | CHIKV VLP/adjuvant, Placebo | Bavarian Nordic, Emergent BioSolutions | Chikungunya Virus | 06/23 | 08/23 | | |
2023-001124-42: A Phase 3 Clinical Trial to evaluate PXVX0317, a virus-like particle vaccine for active immunization to prevent disease caused by chikungunya virus. |
|
|
| Not yet recruiting | 3 | 3150 | US | CHIKV VLP vaccine, PXVX0317, Suspension for injection | Bavarian Nordic A/S, Bavarian Nordic A/S | Healthy Volunteers (Chikungunya disease. Prevention of Chikungunya disease by use of a vaccine), Healthy Volunteers (Prevention of Chikungunya disease), Diseases [C] - Virus Diseases [C02] | | | | |
NCT06007183: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination |
|
|
| Recruiting | 3 | 800 | US | CHIKV VLP vaccine booster, PXVX0317, Placebo booster | Bavarian Nordic | Chikungunya Virus Infection | 04/28 | 08/28 | | |
2015-003556-44: investigational Chikungunya virus (CHIKV) vaccine study to evaluate the safety and Immunogenicity of a Chikungunya Virus |
|
|
| Not yet recruiting | 2 | 400 | Europe | VRC-CHKVLP059-00-VP, VRC-CHKVLP059-00-VP, Solution for injection in pre-filled syringe | IMEA Fondation Leon Mba, FHI360 | To evaluate the safety and tolerability of VRC-CHKVLP059-00-VP vaccin in healthy adults that reside in CHIKV endemic ., To evaluate the safety and tolerability of VRC-CHKVLP059-00-VP in healthy adults that reside in CHIKV endemic, Body processes [G] - Immune system processes [G12] | | | | |
| VXA-CoV2-1 / Vaxart, Emergent Biosolutions |
NCT05067933: A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine |
|
|
| Completed | 2 | 66 | US | VXA-CoV2-1.1-S, Oral Tableted Ad5 COVID-19 Vaccine, Placebo Tablets | Vaxart | COVID-19 | 05/22 | 08/23 | | |
NCT06672055: A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection |
|
|
| Recruiting | 2 | 10000 | US | VXA-CoV2-3.1, COMIRNATY®, Pfizer-BioNTech mRNA Vaccine | Vaxart | SARS-CoV2, COVID-19 | 01/26 | 01/26 | | |
| Vaxzevria (ChAdOx1-S recombinant) / University of Oxford, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca |
| Ongoing | 4 | 4000 | Europe | Concentrate for dispersion for injection, Dispersion for injection, Suspension for injection, , Comirnaty, Spikevax, Vaxzevria, Tutkimuksen kohteena ovat Suomen kansallisen koronarokoteohjelman tarjoamat COVID-19 rokotteet. Tämä koskee myös tutkimuksen aikana tällaiseen käyttöön tulevia COVID-19 rokotteita, mukaan lukien yhdistelmärokotteet. | Finnish Institute for Health and Welfare, Finnish Institute for Health and Welfare | Tutkittavat ovat terveitä (Immuniteetti COVID-19 infektiota vastaan), Tutkittavat ovat terveitä (Immuniteetti COVID-19 infektiota vastaan), Body processes [G] - Immune system processes [G12] | | | | |
2021-000880-63`ACTRN12609000047291: COVID-19 vaccine in patients with rheumatic diseases: The impact of treatments on the vaccine response protection against infection (COVID19-REUMA) COVID19 vaccin hos patienter med reumatiska sjukdomar: effekter av behandlingen på vaccinsvar och skydd mot infektion |
|
|
| Ongoing | 4 | 868 | Europe | Comirnaty, COVID-19 Vaccine AstraZeneca, COVID-19 Vaccine Moderna, Injection, Comirnaty, COVID-19 Vaccine AstraZeneca, COVID-19 Vaccine Moderna | Skåne University Hospital, department of rheumatology in Lud and Malmö, Skåne University Hospital, Department of rheumatology in Lund and Malmö | Pre-hypertension | | | | |
2021-001054-57: SARS-CoV-2 vaccination study in people living with HIV SARS-CoV-2 vaccinatie studie in mensen die leven met HIV |
|
|
| Ongoing | 4 | 1650 | Europe | COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 Vaccine (ChAdOx1-S [recombinant]), EMEA/H/C/005791, EMEA/H/C/005735, EMEA/H/C/005675, Dispersion for injection, Concentrate for dispersion for infusion, Suspension for injection, COVID-19 Vaccine Moderna, Comirnaty, COVID-19 Vaccine AstraZeneca | OLVG, ZonMW | COVID-19 vaccine response in people living with HIV COVID-19 vaccinatie respons in mensen die leven met HIV, COVID-19 vaccination effect in people living with HIV COVID-19 vaccinatie effect in mensen die leven met HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2021-000206-17: Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County, with regard to vaccinations. Studier av pågående och genomgången SARS-CoV-2 infektion (som orsakar COVID-19) inom vård och omsorg i Stockholms län, med avseende på vaccinationer. |
|
|
| Ongoing | 4 | 10000 | Europe | Concentrate for solution for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca | Karolinska University Hospital, Karolinska University Hospital | Vaccination against COVID-19. Vaccination mot COVID-19., Vaccination against COVID-19. Vaccination mot COVID-19., Diseases [C] - Virus Diseases [C02] | | | | |
2021-000710-42: Research into the effect of the COVID-vaccine in patients who are treated with rituximab (RTX-COVAC study) Onderzoek naar het effect van de COVID-vaccinatie bij patiënten die behandeld worden met rituximab (de RTX-COVAC studie). |
|
|
| Ongoing | 4 | 270 | Europe | COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca, Concentrate for solution for injection, Dispersion for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca | Sint Maartenskliniek, Sint Maartenskliniek | Rheumatoid arthritis Reumatoïde artritis, Rheumatic disease Reuma, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2021-000566-14: Post-authorization Phase IV effectiveness and safety multicentric study of COVID-19 vaccines – CoVigi Poregistrační multicentrická studie fáze IV sledující účinnost a bezpečnost vakcín proti COVID-19 – CoVigi |
|
|
| Ongoing | 4 | 500 | RoW | Suspension for injection, Dispersion for injection, COVID-19 VACCINE ASTRAZENECA, COVID-19 VACCINE MODERNA, COMIRNATY | Masarykova univerzita, Masarykova univerzita | COVID-19 Vaccines, monitoring of adverse events and evaluation of the immune response Vakcíny proti COVID-19, sledování nežádoucích účinků a stanovení imunitní odpovědi, COVID-19 Vaccines, monitoring of adverse events and evaluation of the immune response Vakcíny proti COVID-19, sledování nežádoucích účinků a stanovení imunitní odpovědi, Diseases [C] - Virus Diseases [C02] | | | | |
2021-000440-22: Vaccination against COVID-19 in Pregnant and Lactating Women in Belgium |
|
|
| Ongoing | 4 | 420 | Europe | Comirnaty, Covid19 Vaccine Moderna, Covid 19 Vaccine AstraZeneca, J07BX03, Injection, Comirnaty, Covid-19 Vaccine Moderna, COVID19 Vaccine Astrazeneca | Universiteit Antwerpen, Sciensano | Vaccine responses to COVID19 vaccines administered in pregnant andlactating women, Corona virus vaccine responses in pregnant and lactating women, Diseases [C] - Virus Diseases [C02] | | | | |
2021-000349-42: Evaluation of How Long Immune Responses to SARS-CoV-2 Persist Following COVID-19 Vaccination |
|
|
| Ongoing | 4 | 500 | Europe | Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca | Sahlgrenska Academy, University of Gothenburg | COVID-19, COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
2021-001414-10: Response to corona vaccination in patients with primary Sjögren's syndrome |
|
|
| Ongoing | 4 | 180 | Europe | Dispersion for injection, Suspension for injection, Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 Vaccine AstraZeneca suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant]), COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant]) | University Medical Center Groningen, Dutch Association of Sjögren patients (NVSP) | Primary Sjögren's syndrome, Primary Sjögren's syndrome, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-000988-68: Immune response after covid-19 vaccination in patients with renal failure stadium 4 or 5 . Immunologiskt svar vid vaccination mot covid- 19 av patienter med njursvikt stadium 4 eller 5. |
|
|
| Ongoing | 4 | 60 | Europe | COVID-19 Vaccine AstraZeneca, Comirnaty, COVID-19 Vaccine Moderna, Suspension for injection, Concentrate for solution for injection, Dispersion for injection, COVID-19 Vaccine AstraZeneca, Comirnaty, COVID-19 Vaccine Moderna | Region Stockholm, Region Örebro och Region Stockholm | Renal failure stage 4 and 5. Njursvikt stadium 4 och 5, Kidney disease Njursjukdom, Body processes [G] - Immune system processes [G12] | | | | |
| Ongoing | 4 | 150 | Europe | Concentrate for dispersion for infusion, Concentrate for solution for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca | Department of Oncology, Uppsala University Hospita, Department of Oncology, Uppsala University Hospital | Immune response to Covid-19 vaccination of patients with immune modulatory treatment for cancer, Response to Covid-19 vaccination in patients with treatment for cancer, Body processes [G] - Immune system processes [G12] | | | | |
2021-001655-13: SARS-CoV2 vaccination and activation of the clotting system |
|
|
| Ongoing | 4 | 40 | Europe | COVID-19 Vaccine AstraZeneca, Solution for injection, COVID-19 Vaccine AstraZeneca | Radboudumc, Radboudumc | Coronavirus disease 2019 and thromboembolism, corona en trombose, Diseases [C] - Virus Diseases [C02] | | | | |
2021-001769-19: Immune response to SARS-CoV-2 in health care workers, previously infected subjects, and immunocompromised subjects, before and after Covid-19 vaccination: a phase IV trial |
|
|
| Ongoing | 4 | 1200 | Europe | Injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca, COVID-19 Vaccine Janssen | GUVAX (Gothenburg University Vaccine Research Institute), SciLife | SARS-COV-2 infection, Coronavirus disease, Diseases [C] - Virus Diseases [C02] | | | | |
2021-001103-32: Response of the immune system to Covid-19 vaccination in liver disease Reaktion des Immunsystems auf eine Covid-19 Impfung bei Lebererkrankung |
|
|
| Not yet recruiting | 4 | 500 | Europe | Concentrate for suspension for injection, Injection, Comirnaty, Covid-19 Vaccine Moderna, Vaxzevria Injection Suspension | Medical University of Graz, Medical University of Graz | Cirrhotic chronic liver disease Chronische Lebererkrankung im Zirrhosestadium, Advanced chronic liver disease Fortgeschrittene Lebererkrankung, Body processes [G] - Immune system processes [G12] | | | | |
2021-001993-52: Immunogenicity after COVID-19 vaccines in adapted schedules |
|
|
| Not yet recruiting | 4 | 560 | Europe | Dispersion for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, Vaxzevria | University of Antwerp, Belgian Health Care Knowledge Centre (KCE) | Coronavirus disease-19 (COVID-19), COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
2021-001976-40: SARS-Cov-2 vaccine responsiveness in middle-aged and older persons |
|
|
| Not yet recruiting | 4 | 1700 | Europe | Suspension for injection, Comirnaty, Spikevax, Vaxzevria, COVID-19 Vaccine Janssen | National Institute for Public Health and the Environment, National Institute for Public Health and the Environment | SARS-CoV-19, frailty, COVID-19, frailty, Body processes [G] - Immune system processes [G12] | | | | |
2021-002245-15: An observational study to investigate the effectiveness and safety of Corona vaccines in patients with rheumatologic diseases. Beobachtungsstudie zur Untersuchung der Wirksamkeit und Sicherheit von Corona-Impfstoffen bei Patienten mit rheumatologischen Erkrankungen |
|
|
| Ongoing | 4 | 250 | Europe | Solution for injection, Comirnaty, Vaxzevria, COVID-19 Vaccine Janssen, COVID-19 Vaccine Moderna | Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin | Auto Immune Rheumatic Diseases (AIRD) and patients without rheumatic autoimmune diseases (control group). rheumatische Autoimmunerkrankungen und Patienten ohne rheumatische Autoimmunerkrankungen (Kontrollgruppe), rheumatic diseases rheumatische Erkrankungen, Body processes [G] - Immune system processes [G12] | | | | |
2021-002327-38: PREGCOVAC-19: the follow up of pregnant women who received COVID-19 vaccination in the Dutch national vaccination program |
|
|
| Ongoing | 4 | 100 | Europe | Comirnaty, COVID-19 Vaccine Janssen, Moderna-COVID-19-vaccin, Vaxzevria, EMEA/H/C/005735, EMEA/H/C/005737, EMEA/H/C/005675, Injection, Comirnaty, COVID-19 Vaccine Janssen, COVID-19 vaccine Moderna, Vaxzevria | Academic Medical Center, Academic Medical Center | Pregnant women aged ≥ 18 years who are scheduled for COVID-19 vaccination within the Dutch national vaccination program with any of the currently or future available vaccines that are used for pregnant women in the Dutch national vaccination program., Pregnant women aged ≥ 18 years who are scheduled for COVID-19 vaccination within the Dutch national vaccination program., Diseases [C] - Virus Diseases [C02] | | | | |
2021-002363-22: Vaccination of older persons against SARS-CoV2 and inducing cellular immunity |
|
|
| Not yet recruiting | 4 | 150 | Europe | Suspension for injection, Comirnaty, Spikevax, Vaxzevria, COVID-19 Vaccine Janssen | National Institute for Public Health and the Environment, National Institute for Public Health and the Environment | SARS-CoV-19, frailty, COVID-19, frailty, Body processes [G] - Immune system processes [G12] | | | | |
2021-002613-34: Effectivity of COVID-19 vaccination in people with Down syndrome |
|
|
| Ongoing | 4 | 640 | Europe | Concentrate for dispersion for injection, Dispersion for injection, Suspension for injection, Comirnaty COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 Vaccine Moderna, Vaxzevria | University Medical Center Utrecht, ZonMw | Persons with Down syndrome, Persons with Down syndrome, Body processes [G] - Immune system processes [G12] | | | | |
2021-004016-26: Substudy "Responses to Covid-19 vaccines" in research "Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection" "COVID-19 infektion taudinkuva, immuunivaste, genetiikka ja patogeneesi"- tutkimuksen alatutkimus "Koronarokotteen aikaan saama vaste" |
|
|
| Ongoing | 4 | 1000 | Europe | Comirnaty, Vaxzevria, Spikevax, Injection, Comirnaty, Vaxzevria, Spikevax | Meilahti Vaccine Research Center - Helsinki University Hospital | None, None, Body processes [G] - Immune system processes [G12] | | | | |
2021-004419-14: COVID-19 infections in hospital personnel COVID-19 -infektiot sairaalahenkilökunnalla |
|
|
| Ongoing | 4 | 1000 | Europe | Concentrate and solvent for suspension for injection, Concentrate for solution for injection, Concentrate for dispersion for injection, Comirnaty, Vaxzevria, Spikevax | Turku University Hospital, Turku University Hospital, University of Turku, Jane and Aatos Erkko Foudation, The Academy of Finland | COVID-19 COVID-19, COVID-19 COVID-19, Body processes [G] - Immune system processes [G12] | | | | |
| Ongoing | 4 | 2600 | Europe | Corminaty, Spikevax, Vaxzevria, Concentrate for solution for injection, Comirnaty COVID-19 mRNA-vaccine, Spikevax COVID-19-mRNA vaccine, Vaxzevria COVID-19-vaccin (ChAdOx1-S [recombinant]) | Ziekenhuis Oost-Limburg A.V., Ziekenhuis Oost-Limburg A.V., Roche Diagnostics International Ltd, Interreg Euregio Meuse-Rhine | efficiency and durability of the humoral immune response after vaccination against SARS-CoV-2, Immune response after vaccination against COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
2021-004891-33: COVID-19 vaccine induced immune response in patients with primary antibody deficiency COVID-19 rokotuksen synnyttämät immuunivasteet primaarista vasta-ainepuutosta sairastavilla potilailla |
|
|
| Ongoing | 4 | 50 | Europe | Comirnaty, active substance tozinameran, Vaxzevria, active substance: adenovirus encoding SARS-CoV-2 virus spikeprotein ChAdOx1-S, Spikevax, active substance: elasomeran, Concentrate and solvent for suspension for injection, Concentrate and solvent for solution for injection, Concentrate for dispersion for injection, Comirnaty, Vaxzevria, Spikevax | Turku University Hospital, Turku University Hospital, University of Turku, Jane and Aatos Erkko Foundation, The Academy of Finland | COVID-19 COVID-19, COVID-19 COVID-19, Body processes [G] - Immune system processes [G12] | | | | |
2021-001459-15: Immune response to COVID-19 Vaccination in people with Diabetes Mellitus Immunantwort auf COVID-19 Impfung bei Personen mit Diabetes Mellitus |
|
|
| Not yet recruiting | 4 | 160 | Europe | COVID-19 Vaccine AstraZeneca, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine Janssen, EMEA/H/C/005675, EMEA/H/C/005735, EMEA/H/C/005791, EMEA/H/C/005737, Injection, COVID-19 Vaccine AstraZeneca, Comirnaty, COVID-19 vaccine Moderna, COVID-19 Vaccine Janssen | Medical University of Graz, Medical University of Graz | Type 1 Diabetes MellitusType 2 Diabetes Mellitus Diabetes Mellitus Typ 1Diabetes Mellitus Typ 2, Type 1 Diabetes MellitusType 2 Diabetes Mellitus Diabetes Mellitus Typ 1Diabetes Mellitus Typ 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT04914832: Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death |
|
|
| Completed | 4 | 75012 | RoW | AZD1222 | Shabir Madhi, AstraZeneca | COVID-19, Pneumonia, Viral | 09/22 | 09/22 | | |
VICTORIA, NCT05057897: A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults |
|
|
| Terminated | 4 | 34 | RoW | AZD1222 | AstraZeneca | COVID-19, SARS-CoV-2 | 04/23 | 04/23 | | |
NCT05343871: Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial |
|
|
| Completed | 4 | 2354 | RoW | Sinovac, AZD1222, BNT162b2 | Albert B. Sabin Vaccine Institute, Aga Khan University, Oswaldo Cruz Foundation, Stanford University | COVID-19 | 07/23 | 01/24 | | |
NCT04775069: Antibody Response to COVID-19 Vaccines in Liver Disease Patients |
|
|
| Completed | 4 | 232 | RoW | BNT162b2, CoronaVac, AZD1222 | Humanity & Health Medical Group Limited | Chronic Liver Disease | 09/23 | 09/23 | | |
2021-006877-44: Factors that influence the formation of Corona-specific antibodies Faktoren welche die Entstehung von Corona-spezifischen Antikörpern beeinflussen können. |
|
|
| Not yet recruiting | 4 | 2000 | Europe | BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, Ad26.COV2-S, EMEA/H/C/005735, EMEA/H/C/005791, EMEA/H/C/005675, EMAE/H/C/005737, , Solution for injection/infusion, Solution for injection, BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, Ad26.COV2-S | Fachhochschule Salzburg GmbH, Fachhochschule Salzburg GmbH | Prevention or lindering of the symtoms in the course of a covid-19 disease due to vaccination with SARS-CoV-2 directed vaccins. Vorbeugung oder Linderung von Symptomen einer Covid-19 Erkrankung durch die Impfung mittels eines SARS-CoV-2 spezifischen Impfstoff., Prevention or lindering of the symtoms in the course of a covid-19 disease due to vaccination with Corona virus directed vaccins. Vorbeugung oder Linderung von Symptomen einer Covid-19 Erkrankung durch die Impfung mittels eines Corona Virus-spezifischen Impfstoff., Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 4 | 7600 | Europe | COMIRNATY - BioNTech Manufacturing GmbH, COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH, COVID-19 Vaccine AstraZeneca suspension for injection | Jens D Lundgren, MD, Ministry of the Interior and Health, Denmark | SARS-CoV Infection | 12/23 | 12/23 | | |
NCT05715944: Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 |
|
|
| Completed | 3b | 10888 | RoW | AZD 1222, ChAdOx1 nCoV-19 | Botswana Harvard AIDS Institute Partnership, AstraZeneca, Botswana Ministry of Health | COVID-19 | 12/22 | 12/22 | | |
| Completed | 3 | 32450 | US, RoW | AZD1222, Placebo | AstraZeneca, Iqvia Pty Ltd | COVID-19, SARS-CoV-2 | 03/21 | 02/23 | | |
| Completed | 3 | 4034 | Europe | VLA2001, AZD1222, VLA2001 - adolescent part, Placebo | Valneva Austria GmbH | SARS-CoV-2 Virus Infection | 07/21 | 03/23 | | |
NCT04536051: A Study of a Candidate COVID-19 Vaccine (COV003) |
|
|
| Recruiting | 3 | 10300 | RoW | ChAdOx1 nCoV-19 single dose + paracetamol, MenACWY single dose + paracetamol, ChAdOx1 nCoV-19 two dose + paracetamol, MenACWY prime & saline placebo boost + paracetamol | University of Oxford | Coronavirus | 09/21 | 09/21 | | |
NCT05426343: A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222 |
|
|
| Completed | 3 | 200 | RoW | MVC-COV1901, AZD1222 | Medigen Vaccine Biologics Corp. | COVID-19 Vaccine | 10/22 | 01/23 | | |
NCT05198596: A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above |
|
|
| Completed | 3 | 250 | RoW | MVC-COV1901, AZD1222 | Medigen Vaccine Biologics Corp. | COVID-19 Vaccine | 11/22 | 03/23 | | |
NCT05442684: A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine |
|
|
| Withdrawn | 3 | 1350 | NA | Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation, mRNA-based COVID-19 vaccine | CanSino Biologics Inc. | COVID-19 | 03/23 | 06/23 | | |
NCT05534035: Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older |
|
|
| Not yet recruiting | 3 | 450 | NA | PTX-COVID19-B, Vaxzevria® | Everest Medicines (Singapore) Pte. Ltd. | SARS-CoV-2 Infection | 04/23 | 10/23 | | |
NCT05188677: Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults |
|
|
| Completed | 3 | 1831 | RoW | Candidate vaccine, SCB-2019, Comirnaty Vaccine, Vaxzevria Vaccine, CoronaVac Vaccine | Clover Biopharmaceuticals AUS Pty Ltd | COVID-19 | 06/23 | 06/23 | | |
NCT05572879: A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults |
|
|
| Completed | 3 | 2600 | RoW | EuCorVac-19, ChAdOx1 nCoV-19, COVISHIELD | EuBiologics Co.,Ltd | COVID-19 | 06/23 | 02/24 | | |
NCT05603052: A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older |
|
|
| Completed | 3 | 2852 | RoW | EuCorVac-19, ChAdOx1 nCoV-19, COVISHIELD | EuBiologics Co.,Ltd | COVID-19 | 01/24 | 01/24 | | |
NCT05387317: Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia) |
|
|
| Withdrawn | 3 | 800 | RoW | Pfizer-BioNTech Standard dose, BNT162b2, Comirnaty, AstraZeneca Standard dose, ChAdOx1-S, Vaxzevria, Pfizer-BioNTech Fractional dose, AstraZeneca Fractional dose, Moderna Standard dose, mRNA-1273, Spikevax®, Moderna Fractional dose | Murdoch Childrens Research Institute, Universitas Padjadjaran, Health Development Policy Agency, Ministry of Health Republic of Indonesia, Coalition for Epidemic Preparedness Innovations, The Peter Doherty Institute for Infection and Immunity, Indonesia University | COVID-19 | 01/25 | 10/25 | | |
ASU-VAC, NCT04885764: Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University |
|
|
| Recruiting | 2/3 | 4000 | RoW | Astrazeneca/Oxford Vaccine, Vaxzevria, Sinopharm vaccine | Ain Shams University | Covid19 | 10/21 | 12/21 | | |
NCT05059106: EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19 |
|
|
| Recruiting | 2/3 | 29637 | RoW | Half dose of ChAdOx1 nCoV-19 (AZD1222), Standard dose of ChAdOx1 nCoV-19 (AZD1222) | Federal University of Espirito Santo, Instituto René Rachou/Fiocruz, Escola Nacional de Saúde Pública Sérgio Arouca/Fiocruz, Programa de Computação CientÃfica/Fiocruz, Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória | SARS-CoV-2 | 06/22 | 10/22 | | |
2021-002530-17: A Phase 3 study, blinded in vaccinated and unvaccinated adults to determine the safety and immune response of AZD2816, a vaccine for the prevention of COVID-19 caused by variant strains |
|
|
| Not yet recruiting | 2/3 | 2849 | Europe | AZD1222, AZD2816, Solution for injection, Vaxzevria | AstraZeneca AB, AstraZeneca AB | SARS-COV-2 infection (COVID-19), COVID-19, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Active, not recruiting | 2/3 | 12390 | Europe | ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, Menveo, Nimenrix, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost, Two dose MenACWY vaccine, ChAdOx1 nCoV-19 (qPCR), ChAdOx1 nCoV-19 0.5mL prime plus boost, Two dose MenACWY vaccine min. 4 weeks apart, Two dose ChAdOx1 nCoV-19/Covishield 0.5mL, Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL | University of Oxford | Coronavirus | 03/24 | 03/24 | | |
NCT05542693: Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine |
|
|
| Not yet recruiting | 2b | 300 | NA | RNA MCTI CIMATEC HDT 5µg, RNA MCTI CIMATEC HDT 10µg, Covishield® - AstraZeneca, Comirnaty® - Pfizer | Azidus Brasil, SENAI CIMATEC | COVID-19, COVID-19 Vaccine | 03/23 | 09/23 | | |
2021-001978-37: A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the safety and immunogenicity of one dose of COMIRNATY in subjects that had received one dose of VAXZEVRIA. Ensayo clÃnico de Fase II, comparativo, aleatorizado , adaptativo para evaluar la seguridad e immunogenicidad de una dosis de COMINARTY en sujetos que hayan recibido una dosis de VAXZERIA. |
|
|
| Ongoing | 2 | 600 | Europe | Comirnaty, Dispersion for injection, COMIRNATY. Concentrado para dispersión inyectable | Instituto de Salud Carlos III. ISCIII, ISCIII | Covid-19 Vaccination Vacunación Covid-19, Covid-19 Vaccination Vacunación Covid-19, Diseases [C] - Virus Diseases [C02] | | | | |
| Active, not recruiting | 2 | 676 | Europe | COMIRNATY, COVID19, mRNA vaccine | Spanish Clinical Research Network - SCReN, Instituto de Salud Carlos III | Covid19 | 05/21 | 04/22 | | |
2021-002348-57: A Randomized, Parallel Group, Single-Blind, Phase 2 Study to Evaluate the immune response of two classes of SARS-Cov-2 Vaccines employed as Second Boost in Patients under current Rituximab Therapy and no humoral response after standard mRNA vaccination |
|
|
| Ongoing | 2 | 60 | Europe | Comirnaty, BNT162B2, Injection, Comirnaty concentrate for dispersion for injection, COVID-19 Vaccine Moderna dispersion for injection, Vaxzevria | Medical University of Vienna, Medical University of Vienna | Vaccination against SARS-CoV-2 in patients with rituximab therapy, Rituximab has been shown to impair humoral responses to various vaccines including SARS-CoV-2 vaccination., Diseases [C] - Immune System Diseases [C20] | | | | |
2021-002927-39: Preventive strategies against SARS-CoV-2 in kidney transplant recipients:Intervention A - vaccination: Study to test if vaccination with Ad26COVS1 or ChAdOx1-S results in a better immune response compared to a third dose of BNT162b2 or mRNA-1273 in kidney transplant recipients who did not develop an immune response following previous vaccination against COVID-19Intervention B - monoclonal SARS-CoV-2 antibody cocktail in kidney transplant recipients not responding to vaccination |
|
|
| Not yet recruiting | 2 | 400 | Europe | EVUSHELD, AZD7442, Suspension for injection, Concentrate for dispersion for injection, Dispersion for injection, Lyophilisate for solution for injection, COVID-19 Vaccine Janssen, Comirnaty, COVID-19 Vaccine Moderna, Vaxzevria | Medical University of Vienna, Medical University of Vienna | Intervention A - vaccinationPatients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccineSubstudy A: kidney transplant recipients who did not develop antibodies after a fourth doseIntervention B - monoclonal antibodiesKidney transpant recipients who do not develop neutralizing antibodies after at least two doses of SARS-CoV-2 vaccine, Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following vaccination, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05027672: Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines. |
|
|
| Active, not recruiting | 2 | 348 | RoW | Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5), Gam-COVID-Vac (rAd26) / ChAdOx1 nCoV-19, Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd26), Gam-COVID-Vac (rAd26) / mARN-1273 | Ministerio de Salud de Ciudad Autónoma de Buenos Aires | COVID-19 Vaccines | 08/21 | 09/21 | | |
NCT04983537: Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population |
|
|
| Recruiting | 2 | 120 | RoW | Gam-COVID-Vac / Gam-COVID-Vac, Gam-COVID-Vac / ChAdOx1 nCoV-19, Gam-COVID-Vac / BBIBP-CorV | Ministerio de Salud de Ciudad Autónoma de Buenos Aires | COVID-19 Vaccines | 09/21 | 09/21 | | |
| Recruiting | 2 | 1760 | RoW | COVID-19 vaccines, SPUTNIK-V (Gam-COVID-Vac), SINOPHARM (BBIBP-CorV), AstraZeneca (ChAdOx1 nCoV-19 vaccine AZD1222), Moderna (mRNA-1273 or Spikevax) | Ministry of Public Health, Argentina, Russian Direct Investment Fund | COVID-19 VACCINE, Covid19 | 09/21 | 02/22 | | |
| Recruiting | 2 | 3000 | Europe | Vaxzevria, Comirnaty | Medical University Innsbruck, Medical University of Graz, Medical University of Vienna | SARS-CoV2 Infection | 11/21 | 12/21 | | |
2021-002693-10: A Phase II Study to Evaluate Safety and Efficacy to a Third Vaccination with an mRNA or Vector Vaccine in Patients under Immunosuppressive Therapy no or reduced Responds to Standard mRNA SARS-CoV-2 (Covid-19) Vaccination |
|
|
| Not yet recruiting | 2 | 300 | Europe | Comirnaty, BNT162B2, Dispersion for injection, Comirnaty concentrate for dispersion for injection, Covid-19 Vaccine Moderna dispersion for injection, Vaxzevria | Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology, Medical University of Vienna | Vaccination against SARS-CoV-2 in patients with immunosuppressive therapy or immunodeficiencies, Vaccination against Covid-19 in patients who are under medication which suppresses the immune system or have immunodeficiencies, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05197153: A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 |
|
|
| Completed | 2 | 804 | RoW | Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222, Half dose of mRNA-1273 | Medigen Vaccine Biologics Corp., Coalition for Epidemic Preparedness Innovations | COVID-19 Vaccine | 06/22 | 10/22 | | |
2021-002171-19: Heterologous vaccination with a Vaxzervia (ChAdOx1-S) prime and a Comirnaty (BNT162b2) boost Heterologe Impfung mit Vaxzervia (ChAdOxl-S, AstraZeneca) gefolgt von Comirnaty (BNT162b2, Pfizer) |
|
|
| Not yet recruiting | 2 | 3000 | Europe | Comirnaty, Vaxzevria, Dispersion for injection, Suspension for injection, Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified), Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant]) | Medizinische Universität Innsbruck, Institut für Virologie, Medizinische Universität Innsbruck | Immunization for SARS-CoV-2, Immunisierung gegen SARS-CoV-2, Not possible to specify | | | | |
| Active, not recruiting | 2 | 600 | Europe | COMIRNATY, COVID-19, mRNA vaccine | Instituto de Investigación Hospital Universitario La Paz, Instituto de Salud Carlos III, Spanish Clinical Research Network - SCReN | Covid19 | 08/22 | 12/22 | | |
NCT05054621: Immunogenicity of COVID-19 Vaccine on Heterologous Schedule |
|
|
| Completed | 2 | 100 | RoW | Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous prime-boost schedule with two doses of AZD1222 | Chang Gung Memorial Hospital | Covid-19, Vaccine, Immunogenicity, Reactogenicity, Healthy | 08/22 | 08/22 | | |
| Active, not recruiting | 2 | 669 | Canada | mRNA-1273 SARS-CoV-2 vaccine, COVID-19 Vaccine Moderna, Spikevax, BNT162b2, Pfizer-BioNTech COVID-19 Vaccine, Comirnaty, ChAdOx1-S [recombinant], Astra Zeneca COVID-19 Vaccine, COVISHIELD AstraZeneca COVID-19 Vaccine, Vaxzevria, 0, 28 day schedule, 0, 112 day schedule, Covifenz, Medicago COVID-19 vaccine | Canadian Immunization Research Network, Canadian Center for Vaccinology, BC Children's Hospital Research Institute, Children's Hospital Research Institute of Manitoba, CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Ontario Agency for Health Protection and Promotion, University of Toronto, Massachusetts General Hospital, Interior Health, McGill University Health Centre/Research Institute of the McGill University Health Centre | COVID-19 | 11/24 | 02/25 | | |
NCT04444674: COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection |
|
|
| Active, not recruiting | 1/2 | 2130 | RoW | ChAdOx1 nCoV-19, Normal saline 0.9% | University of Oxford, Medical Research Council, South Africa, Bill and Melinda Gates Foundation, Wits Health Consortium (Pty) Ltd, University of Witwatersrand, South Africa | Coronavirus | 12/20 | 12/21 | | |
Isotretinoin, NCT04730895: Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. |
|
|
| Not yet recruiting | 1/2 | 360 | NA | Oral 13 cis retinoic acid, Aerosolized 13 cis retinoic acid, 13 cis retinoic acid doses orally in combination with spike protein based vaccine, Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine, Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine | Kafrelsheikh University | Covid19 Vaccine | 09/21 | 12/23 | | |
| Recruiting | 1/2 | 550 | RoW | ChAdOx1 nCoV-19 vaccine (AZD1222) | Federal University of Espirito Santo, Instituto René Rachou/Fiocruz | SARS-CoV-2 Infection | 08/22 | 12/23 | | |
COVAXAER01, NCT05007275: A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers |
|
|
| Active, not recruiting | 1 | 28 | Europe | 1x10^9 vp AZD1222, 5x10^9 vp AZD1222, 1x10^10 vp AZD1222 | Imperial College London, University of Oxford, AstraZeneca | Covid19, SARS-CoV-2 Infection | 06/24 | 06/24 | | |
| Active, not recruiting | N/A | 70 | Europe | BNT162b2, Comirnaty®, tozinameran, AZD 1222, Vaxzevria®, Covishield®, ChadOx1 nCoV-19, mRNA-1273, Spikevax®, elasomeran | University Medicine Greifswald | SARS-CoV-2 Vaccination | 12/21 | 12/23 | | |
NCT04794946: Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis |
|
|
| Recruiting | N/A | 2200 | RoW | Covishield | Institute of Liver and Biliary Sciences, India | Liver Cirrhosis | 03/22 | 03/22 | | |
NCT05052307: A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil |
|
|
| Completed | N/A | 4574 | RoW | Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine, CoronaVac COVID-19 vaccine, ChAdOx1 nCoV-19 Covid-19 Vaccine, Ad26.COV2.S COVID-19 Vaccine | Hospital Moinhos de Vento, Universidade Federal do Paraná, Pfizer, Inova Medical | Covid19 | 06/22 | 07/23 | | |
PRIDE, NCT05145348: Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome. |
|
|
| Recruiting | N/A | 640 | Europe | Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) | UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development, National Institute for Public Health and the Environment (RIVM), Stichting Downsyndroom (SDS), Sanquin Research & Blood Bank Divisions | Down Syndrome, SARS-CoV-2 Vaccination | 06/22 | 06/23 | | |
NCT04832932: The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes |
|
|
| Active, not recruiting | N/A | 2000 | Europe, US, RoW | COVID-19 vaccines, BNT162b2, mRNA-1273, JNJ-78436735, AZD1222, Gam-KOVID-Vak, CoronaVac/Sinovac, BBIBP-CorV, BBV152, NVX-CoV2373 | Mebo Research, Inc., Aurametrix | COVID-19 Vaccines | 01/23 | 01/25 | | |
| Completed | N/A | 188814085 | RoW | ChAdOx1 nCOV-19 vaccine (Vaxzeria), BNT162b2 (Pfizer), Ad26.COV2.S (Janssen), CoronaVac (Sinovac) | AstraZeneca | COVID-19 | 05/23 | 05/23 | | |
| Completed | N/A | 5321930 | Europe | AZD1222 | AstraZeneca, RTI Health Solutions | COVID-19, Vaccine Adverse Events of Special Interest | 01/24 | 01/24 | | |
NCT05135455: VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA |
|
|
| Completed | N/A | 467 | Japan | | AstraZeneca | Prevention of Infectious Disease Caused by SARS-CoV-2 | 08/23 | 08/23 | | |
NCT05110911: Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection |
|
|
| Recruiting | N/A | 1500 | RoW | Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad, SARS-CoV-2 vaccination: Comirnaty or Vaxzevria | University of Melbourne, The University of Queensland, Sydney Children's Hospitals Network, The Alfred, University of Adelaide, The University of Western Australia, London School of Hygiene and Tropical Medicine, University of Newcastle, Australia | Influenza, Human, SARS-CoV-2 Infection | 11/23 | 11/23 | | |
| Active, not recruiting | N/A | 1286 | Canada | mRNA Vaccines or Viral vector-based vaccines for COVID, Moderna Spikevax COVID-19 vaccine, Pfizer-BioNTech Comirnaty COVID-19 vaccine, AstraZeneca Vaxzevria COVID-19 vaccine, Janssen (Johnson & Johnson) COVID-19 vaccine | University Health Network, Toronto, Canadian Institutes of Health Research (CIHR), Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Public Health Agency of Canada (PHAC) | COVID-19 Virus Infection, Vaccine Response | 03/24 | 04/24 | | |
